The Europe acute pancreatitis market was valued at US$ 1,492.10 million in 2022 and is expected to reach US$ 2,260.69 million by 2030; it is estimated to grow at a CAGR of 5.3% from 2022 to 2030.
As per the European Review for Medical and Pharmacological Sciences, published in 2022, the prevalence of pancreatogenic diabetes is 5-10% in the Western diabetic population, and chronic pancreatitis is responsible for 20% of cases while acute pancreatitis causes 80% of cases. According to an article published in the National Library of Medicine in 2021, ~23% of acute pancreatitis patients are likely to develop diabetes within three years of discharge. Further, an article published in the Journal of Gastroenterology in 2020 states that following acute pancreatitis, ~3%, 7%, 9%, and 11% of patients develop diabetes at 6, 12, 18, and 24 months of discharge, respectively. According to an article published in the MDPI, in 2023, ~40% of patients with acute pancreatitis are affected by prediabetes and diabetes and are at a higher risk of death and readmission to hospitals than patients with type 2 diabetes. Further, ~ 60.2% of adult patients developed diabetes after acute pancreatitis, and 9% of children after acute recurrent pancreatitis or with chronic pancreatitis, and this risk increases as they age into adulthood. Researchers have noted higher diabetes incidence (~39%) after severe acute pancreatitis than mild acute pancreatitis (14%) in a meta-analysis comparing severe and mild acute pancreatitis. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the Europe acute pancreatitis market.
Based on offerings, the Europe acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on method, the Europe acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the Europe acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Europe acute pancreatitis market is segmented into the U.K., Germany, France, Italy, Spain, the Nordic Countries, the Netherlands, and the Rest of Europe. Germany dominated the Europe acute pancreatitis market share in 2022.
Abbott Laboratories, Actim Oy, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the Europe acute pancreatitis market.
Reasons to Buy
Rising Incidence of Diabetes Following Acute Pancreatitis Fuels the Europe Acute Pancreatitis Market
The pancreas produces insulin, a hormone that regulates blood sugar levels. Pancreatitis can harm insulin-producing cells of pancreas, which causes diabetes in patients suffering from acute pancreatitis. People suffering from acute pancreatitis are at a twofold greater risk of diabetes as compared to the general population. Diabetes sequelae are observed across the spectrum of severity in acute pancreatitis and can accompany other clinical complications.As per the European Review for Medical and Pharmacological Sciences, published in 2022, the prevalence of pancreatogenic diabetes is 5-10% in the Western diabetic population, and chronic pancreatitis is responsible for 20% of cases while acute pancreatitis causes 80% of cases. According to an article published in the National Library of Medicine in 2021, ~23% of acute pancreatitis patients are likely to develop diabetes within three years of discharge. Further, an article published in the Journal of Gastroenterology in 2020 states that following acute pancreatitis, ~3%, 7%, 9%, and 11% of patients develop diabetes at 6, 12, 18, and 24 months of discharge, respectively. According to an article published in the MDPI, in 2023, ~40% of patients with acute pancreatitis are affected by prediabetes and diabetes and are at a higher risk of death and readmission to hospitals than patients with type 2 diabetes. Further, ~ 60.2% of adult patients developed diabetes after acute pancreatitis, and 9% of children after acute recurrent pancreatitis or with chronic pancreatitis, and this risk increases as they age into adulthood. Researchers have noted higher diabetes incidence (~39%) after severe acute pancreatitis than mild acute pancreatitis (14%) in a meta-analysis comparing severe and mild acute pancreatitis. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the Europe acute pancreatitis market.
Europe Acute Pancreatitis Market Overview
The Europe acute pancreatitis market is segmented into Germany, the UK, France, Italy, Spain, Nordic Countries, The Netherlands, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of acute pancreatitis and increase in alcohol consumption are the major factors driving the market growth in Europe. According to the Federal Statistical Office, health expenditure in Germany amounted to US$ 460.03 billion in 2019. It is an attractive market for companies offering therapeutic products for acute pancreatitis due to its innovative approach toward healthcare. Medical device manufacturers in Germany can also seek government funding for a variety of research projects and receive grants from the Kreditanstalt für Wiederaufbau (KfW). The increasing focus of manufacturers on new product development and strategic collaborations to develop advanced diagnostic devices such as acute pancreatitis is expected to further propel the market growth in the coming years.Europe Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
Europe Acute Pancreatitis Market Segmentation
The Europe acute pancreatitis market is segmented offerings, causes, end user, and country.Based on offerings, the Europe acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on method, the Europe acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the Europe acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Europe acute pancreatitis market is segmented into the U.K., Germany, France, Italy, Spain, the Nordic Countries, the Netherlands, and the Rest of Europe. Germany dominated the Europe acute pancreatitis market share in 2022.
Abbott Laboratories, Actim Oy, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the Europe acute pancreatitis market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe acute pancreatitis market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Europe acute pancreatitis market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Acute Pancreatitis Market Landscape
5. Europe Acute Pancreatitis Market - Key Industry Dynamics
6. Acute Pancreatitis Market - Europe Market Analysis
7. Europe Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Offerings
8. Europe Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Causes
9. Europe Acute Pancreatitis Market - Revenue and Forecast to 2030 - by End User
10. Europe Acute Pancreatitis Market - Country Analysis
11. Europe Acute Pancreatitis Market-Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Actim Oy
- Baxter International Inc
- Boston Scientific Corp
- Dynavax Technologies Corp
- Fresenius Kabi AG
- GE HealthCare Technologies Inc
- Koninklijke Philips NV
- Medtronic Plc
- Samsung Healthcare
